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INTRODUCTION 
In the United States of America, the use and abuse of opioids has reached epidemic proportions. 
In 2017, the U.S. Department of Health and Human Services declared the opioid crisis a public 
health emergency as the rates of overdose deaths continued to rise. The same year as this 
declaration, more Americans died due to drug overdoses than the number of deaths from 
HIV/AIDS at the peak of the epidemic in 1995. This epidemic has killed more Americans than 
the total number of American deaths in the Vietnam War. The primary driver of these overdose 
deaths is due to opioids, both prescription painkillers such as morphine and oxycodone and illicit 
drugs such as heroin. This paper looks to analyze the various contributing factors leading to 
addiction, and the implications on society with such a large population of Americans facing 
addiction. 
NERVOUS SYSTEM INTRODUCTION 
The nervous system is divided into the central nervous system (CNS) which contains the brain 
and spinal cord, and the peripheral nervous system (PNS) which includes the nerves that travel 
throughout the body. Drug abuse impacts the CNS and many functions involved in heart rate, 
sleeping, and breathing through the brain stem; emotions, including happiness through the limbic 
system; and decision-making abilities through the cerebral cortex. The different parts of the 
human brain can communicate with each other via neurons and neurotransmitters. Neurons are 
brain cells used to relay signals, and neurotransmitters are the chemical messengers that are the 
signals. Each neuron has different receptors, which allow for the binding of a specific 
neurotransmitter; once bound, an action potential can occur which is the propagation of the 
signal down the neuron. There are many different types of neurotransmitters but all fall into two 
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categories: excitatory or inhibitory. Excitatory neurotransmitters will increase the likelihood of a 
response while inhibitory neurotransmitters do the opposite. 
OPIOID NEUROTRANSMITTERS 
There are four main classes of opioids: natural opiates, semi-synthetic opiates, fully synthetic 
opiates, and endogenous opiates. Synthetic and semi-synthetic opioids can interfere with the 
typical neural pathways involved in sending, receiving, and processing information that allows 
the different areas of the brain to communicate with each other. The naturally produced 
endogenous opioids are created in the brain and work to block pain. The opioid epidemic is 
focused around exogenous opioids, which are chemical signals that are not naturally made by the 
human body and are instead often prescribed by a healthcare provider. Exogenous opioids are 
similar in structure to endogenous opioids, and therefore can activate receptors in the brain 
resulting in the same effects as endogenous opioids. Exogenous opioids can alter certain essential 
areas of the brain, such as the brain stem, cerebral cortex, and the limbic system (NIDA, 2014). 
PAIN SENSATION 
One form of communication between neurons involves pain sensation, and many of the pain 
pathways utilize opioid neurotransmitters. Neurons sense injuries that occur to the skin and 
muscles and then signal other neurons in the central nervous system. Pain nerves in the body 
begin to fire less intensely once natural opioids such as endorphins and enkephalins bind to 
receptors. However, in instances when there is chronic pain, pain signals are constant. Natural 
endorphins are not sufficient to deal with this long-lasting chronic pain, and often prescription 
opioids are prescribed (Akpan & Griffin, 2017). 
Opioids, both endogenous and exogenous, affect neural pathways that are involved in 
pain and pleasure perception; these pathways include the dopaminergic and GABA-nergic 
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pathways. Opioids can hijack the normal functioning of the reward pathway and activate neurons 
because the chemical structure resembles that of a natural neurotransmitter. Dopamine is an 
excitatory neurotransmitter that is present in the mesolimbic dopamine pathway of the brain and 
regulates feelings of pleasure and emotion (NIDA, 2014). Opioids function to overstimulate 
neural systems and flood the reward system of the brain with dopamine, releasing 2-10 times the 
amount of dopamine than what is released on a regular basis (Di Chiara & Imperato, 1988). 
There are two main ways that the brain works to return to homeostatic levels of dopamine - there 
will be an overall decreased production of dopamine, or there will be an overall decreased 
production of the number of dopamine receptors. Abuse of exogenous opioids can lead to a 
down-regulation of dopamine receptors. This decrease in dopamine signaling leads to those who 
have been taking opioids being unable to experience even daily pleasures (NIDA, 2014). 
While increasing levels of dopamine, opioids also work to relieve pain in the body by 
suppressing GABA neurotransmission (Basbaum & Fields, 1984). GABA is an inhibitory 
neurotransmitter found throughout the brain and spinal cord that is primarily involved in 
controlling thinking and perceiving. By decreasing the functionality of the inhibitory 
neurotransmitter and increasing the excitatory neurotransmitter, opiates increase feelings of 
pleasure to such intensity that once an individual stops taking the drug, feelings of intense 
withdrawal occur. In normal body functioning, when dopamine levels increase, GABA levels 
tend to increase as well to bring the body back to a homeostatic balance. Opiates, including 
heroin and morphine, function as agonists at the opioid receptors and activate dopamine in the 
ventral tegmental area by inhibiting GABAergic neurons (Johnson & North, 1992). Overall, this 
disinhibition leads to an increase in dopamine neurotransmission and a decrease in GABA 
neurotransmission, which amplifies the signal elicited by dopamine. 
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The need to elicit increased dopamine levels forms the basis for the transition from 
normal reward impulses to addiction. With the consistently elevated levels of dopamine that are 
present with increased intake of drugs, the level of dopamine receptors decreases, and the levels 
of presynaptic dopamine transporters also decrease as a compensatory mechanism (Volkow et 
al., 1993). When opioid drugs are administered repeatedly, the ability of neuronal cells to 
produce endogenous opioids is inhibited, which is part of the reason that withdrawal symptoms 
occur with such extreme discomfort (NIDA, 2014).  
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MOLECULAR MECHANISMS OF OPIOID TOLERANCE 
The inhibition of the neural cells to produce these endogenous opioids also leads to opioid 
tolerance. Tolerance is when the effect of a drug is no longer as strong as it was when first taken, 
leading to higher doses required to induce a similar effect (NIDA, 2014). Substance addiction 
occurs when there has been substance abuse at such a repetitive level that the normal circuitry of 
reward and behaviors is corrupt (Di Chiara & Imperato, 1988). 
Once there are excess exogenous opiates in the nervous system, the neurons begin to 
adapt. The neurons that normally secrete GABA following opioid exposure now begin to 
produce three to four times more cyclic AMP. Cyclic AMP is part of a second messenger system 
and functions in intracellular signaling, allowing the neuron to reach threshold potential. Once 
there is excess cAMP, there is excess neural firing. This adaptation of increased cAMP 
production will continue even when there are no opioids present, and lead to excess GABA 
neurotransmitter signaling in the brain (Akpan, N., & Griffin, J. 2017). 
Calcium also plays a role in the development of opioid tolerance. When there is an acute 
administration of opioid agonists, there is a reduction in the calcium content in synaptic vesicles. 
Since calcium is required for an action potential to begin, the reduced calcium intake caused by 
opioids will indirectly cause an increase in potassium exiting the cell, leading to a shortening of 
the repolarization period and a shortening of the action potential duration. (Chahl, 1996). There 
is a correlation between the ineffective regulation of cAMP caused by opioids and the tolerance 
induced at a molecular level to opioids. When there are chronic levels of morphine exposure, 
there is the potential for the upregulation of adenylyl cyclase and protein kinase A (PKA) 
because opioid receptors couple to adenylate cyclase, which can lead to an inhibition of 
neurotransmitter release as depicted in Figure 2 (Dang & Christie, 2012). 
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Figure 2: Mechanism of Opioid Neurotransmitter Release 
This image depicts the proposed impact opioids have on neurons. By inhibiting calcium entry and 
enhancing potassium exiting, there is an inhibition of neurotransmitter release. Another 
mechanism is the inhibition of adenylate cyclase to have decreased levels of cAMP (Chahl, 1996). 
 
DOPAMINE REWARD PATHWAY 
In 1954, Olds and Milner conducted experiments that established the foundational understanding 
of reward mechanisms in the brain. The researchers gave rodents the option to repeatedly 
administer electrical stimulation to the brain. The regions that elicited “pleasure,” such as the 
nucleus accumbens and the septum, would result in continual voluntary stimulation by the mice 
themselves. The major pathway identified in this reward system was the mesolimbic pathway, 
also known as the dopamine reward pathway. 
The mesolimbic pathway (Figure 3) originates from a group of neurons in the ventral 
tegmental, area (VTA) and terminates in either the nucleus accumbens of the ventral striatum, 
the amygdala, bed nucleus of stria terminalis, lateral septal area, or lateral hypothalamus 
(Gardner & Ashby, 2000). The nucleus accumbens is believed to play an important role with 
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reward while the amygdala is associated with emotion (S.R.W. Stott, S.-L. Ang, 2013). All 
rewarding stimuli increase the concentrations of mesolimbic dopamine in the extracellular 
regions. When drugs activate the neurons in the VTA, there is a release of dopamine into the 
nucleus accumbens leading to feelings of pleasure (Friedman, D.P. & Rusche S., 1999). Opiates 
bind to opiate receptors that send a signal to the dopamine terminal to release more dopamine. 
The activation of opiate receptors leads to a decrease of GABA release, which typically 
functions to inhibit dopamine (NIDA, 2007). Opiates decrease pain and increase pleasure, which 
overall leads to a very addictive neurological combination. 
 
Figure 3: The Mesolimbic Pathway 
Dopaminergic pathways.svg by Patrick J. Lynch is licensed under CC-BY 3.0. 
 
This pathway is also referred to as the dopaminergic pathway and consists of neurons that have 
cell bodies that run the entire length of this pathway. These neurons produce dopamine and can 
send this signal to their destinations. 
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There are many different effects of dopamine, and the various effects are mediated by 
five different transmembrane G-protein coupled receptor subtypes. The D1-receptors activate 
adenylyl cyclase, and the D2-receptors inhibit adenylyl cyclase and activate potassium channels 
leading to an overall potassium efflux, which causes hyperpolarization in the local potentials in 
the cell (Missale et al., 1998). The potassium efflux is counteracting the calcium influx, thus 
reducing the amount of neurotransmitter released.  
OPIOID PATHWAY 
Opioids function by attaching themselves to opioid receptors present on neurons in the brain, 
spinal cord, gastrointestinal tract, and other organs in the body. Once the opiate attaches to these 
receptors, the perception of pain is reduced; however, there are side effects caused by opiates 
such as drowsiness, respiratory depression, mental confusion, nausea, and constipation due to the 
widespread presence of opiate receptors in various neural and physiological pathways (Mattoo, 
2009).  
There are three different types of transmembrane opioid receptors, μ, κ, and δ, to which 
an opioid can bind. Opioid receptors can be activated by endogenous opioid chemicals such as 
endorphins and enkephalins or by exogenous chemicals such as prescription opiates (NIDA, 
2014). All three receptors are located in pain-modulating pathways within the brain, including 
the medulla, locus coeruleus, the limbic system, the midbrain, cortical structures, and the 
periaqueductal gray area (McNicol et al., 2003). Of the three receptors, the μ receptor is 
primarily responsible for the relative effects of opioids and opiate addiction (Akpan, N., & 
Griffin, J. 2017).  
 
10 
 
 
Figure 4: Site of Action for Opioids 
In this figure, there are two pathways, a gray pathway, which depicts pain transmission from the 
PNS to the CNS, and a red pathway, which depicts the pain-modulating neurons in the medulla 
and the mid brain (Al-Hasani & Bruchas, 2011). 
 
 Activation of the opioid receptor by an exogenous opioid causes the second messenger 
system of inhibitory G-protein coupled receptors to be activated. The opioid itself is the first 
messenger and never enters the cell body, but instead binds to a receptor, which causes a series 
of activations and inhibitions in the rest of the signaling pathway. The binding of the opioid to 
the opioid receptor leads to a conformational change in the receptor, activating the coupled G-
protein. The Gi receptor is the mechanism most opiates utilize, and this complex leads to a 
dissociation between the Giα and Giβγ subunits of the G-protein. The Giα molecule inhibits the 
activation of adenylyl cyclase. Adenylyl cyclase is the enzyme that converts ATP to PPi and 
cAMP (Childers & Snyder, 1978). The inhibition of adenylyl cyclase leads to a reduction in the 
cAMP-dependent calcium influx, impacting the polarization of the cell. This disassociation also 
leads to the interaction of Gα protein with Kir3, which is a rectifying potassium channel. By 
11 
 
deactivating the potassium channel, the cell becomes hyperpolarized, and the neural activity will 
be dampened (Ippolito, Temkin, Rogalski, & Chavkin, 2002). A similar mechanism occurs for 
calcium channels, where the disassociated Gβγ subunit directly binds to the channel and reduces 
the opening of voltage-gated calcium channels (Zamponi & Snutch, 2002). As a result, there is a 
coupling to potassium channels and a negative modulation for calcium channels for opioid 
receptors (Al-Hasani & Bruchas, 2011). 
 
 
 
Figure 5: Opioid Receptor Signaling 
This cartoon depicts the common molecular pathway that opioid receptors use. The arrows refer to 
activation while the T lines depict inhibition of a signaling molecule. The MAPK signaling molecules that 
are activated are all kinases that will phosphorylate molecules downstream (Al-Hasani & Bruchas, 2011). 
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SUMMARY OF BRAIN ANATOMY INVOLVED WITH ADDICTION 
The parts of the brain that are involved with the reward pathway are the same as the parts of the 
brain that are involved with addiction. The release of dopamine in the nucleus accumbens leads 
the hippocampus to create a conditioned response to the opiate. Along with the hippocampus, the 
amygdala is typically related to the memory of emotionally arousing events. The hesitation and 
fear present with new stimuli and the assignment in reward values for existing stimuli is done by 
this part of the brain. The memories created by these two parts of the brain lead to a conditioned 
response whenever environmental cues are encountered that remind the individual of their 
previous drug consumption. (Elliott et al., 2000). 
The anterior cingulate is involved with emotional self-control, error detection, and 
adaptive responses to changing conditions. The anterior cingulate also plays a role in processing 
conflicts and performance monitoring. The bed nucleus of the stria terminalis (BNST) is located 
in the extended amygdala and is sensitive to dopamine stimulation. The BNST is involved with 
the autonomic and behavioral reactions such as the stress response to fearful stimuli. 
Experiments have shown that this part of the brain is involved in the reinstatement of a drug 
directly after experiencing a painful stimulus. The dorsolateral prefrontal cortex (DLPFC) is 
involved with the control and regulation of cognitive activities. The holding/maintaining working 
memory for the short-term storage is conducted by the DLPFC. The hippocampus is important 
for acquiring new factual information and forming new memories. Alzheimer’s disease and other 
memory impacting diseases as well as anterograde amnesia are typically the results of damage to 
the hippocampus. (Elliott et al., 2000). 
The orbitofrontal cortex (OFC) is involved when faced with unpredictable situations and 
is implicated with disorders of impulsivity and decision-making. The medial portion of the OFC 
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is connected to the hippocampus and cingulate and is involved with assessing the familiarity of a 
situation to integrate outcome expectancies. The lateral portion of the OFC is connected to the 
amygdala and is associated with suppressing previously rewarded responses in order to provide 
terminating signals for changing behavior. The insular cortex is important for processing pain as 
it receives somatosensory inputs and tends to be activated during acute anxiety. These parts of 
the brain all work together in the mesolimbic dopamine pathway and can all be impacted by 
exogenous opiates (Elliott et al., 2000). 
GENETICS 
While there are many social and economic factors that lead to differences in opioid use disorder 
between racial groups and genders, there are underlying genetic factors that contribute to this 
addiction pathway as well (Mistry et al., 2014). Studies of twins consistently demonstrate that 
familial genetics contribute greatly to addiction (Cadoret, Troughton, & German, 1986). The 
Harvard Twin Study of Substance Abuse shows that there is a 34% contribution from genetic 
influences into the variance of abuse (Tsuang et al., 2001). The heritability involved with 
addiction and drug use behavior is based off multiple genes, and by developing an understanding 
of these genetic markers, there is the potential to change the way opioid abuse is studied and 
treated. 
 The gene that encodes for dopamine receptor D2 (DRD2) is located on chromosome 
11q23 and allows for the production of a seven-transmembrane helix receptor that can inhibit 
adenylyl cyclase through inhibitory G-proteins (Freedman et al., 1994). The allele DRD2 
rs1800497 contains a polymorphism that is associated with heroin dependence. The specific 
polymorphism is at the Taq1 RFLP site rs1800497 and involves a single nucleotide 
polymorphism (SNP). In a study that compared the allele frequencies in 500 Han Chinese opioid 
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addicted subjects, the patients who carried at least one copy of this rs1800497 A1 allele had a 
mean heroin consumption twice as high as those subjects without this allele (Hou & Li, 2009). 
This allele is present at a higher frequency in subjects with opioid use disorder and has been 
associated with successful methadone treatment outcomes (Dalley et al. 2009). In another study 
involving 95 Caucasian opioid addicted subjects, 19% showed the rs1800497 A1 allele, 
compared to the 4.6% occurrence that found in the control subjects with no history of addiction.  
 There are three different types of G-protein coupled opioid receptors – the μ, κ, and δ 
receptors (Dalley et al., 2009). The gene that encodes for Opioid Receptor μ 1 (OPRM1) is 
located on chromosome 6q24-q25 (Kapur et al., 2007). There have been correlations between 
this gene and many physiological symptoms such as respiratory depression, decreased 
gastrointestinal motility, and euphoria (Dalley et al., 2009). There are many SNPs present 
between ethnic variations with opioid abuse and general opioid abuse (Kapur et al., 2007). In an 
analysis of Hispanic subjects, the SNP occurring at A118G (rs1799971) was significantly higher 
in those without any opioid dependency. In a study involving Indian subjects, there was a 31% 
frequency in the A118G SNP gene for those that were opioid dependent (Dond et al., 1998). 
 Other than the receptors themselves, neurotrophic factors also play a regulatory role in 
the nervous system. Brain-derived neurotrophic factor (BDNF) is a protein linked to opioid 
dependence and is encoded by the BDNF gene, which is located on chromosome 11p14 (de Cid 
et al., 2008). Connecting drug use and drug dependence, this protein is imperative in the reward 
pathway and regulating cellular signals. Increased concentrations of BDNF in the ventral 
tegmental area induce over-expression of dopamine receptors leading to a reward state parallel to 
the type achieved with opioid use (Heidt et al., 2007). In a study with Japanese subjects, an SNP 
of the gene G196A (rs6265) indicated a link between depression and genotypes. With female 
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subjects that were homozygous for the G196A allele that encoded for valine, there was a 
significant increase for reward dependence and extraversion, which negatively correlates to 
depression. In contrast, subjects that carried the SNP for methionine were more prone to 
developing depression-related mood disorders. Subjects with the G196A valine allele showed 
increased levels of BDNF, which leads to increased euphoric events (Itoh et al., 2004).  
INTRODUCTION TO PUBLIC HEALTH CONCERNS 
The number of deaths that occurred in the United States from prescription opioids more than 
quadrupled between 1999-2010 (Volkow et al., 2014). The Council of Economic Advisors 
estimates that in 2015 the economic cost of the opioid crisis was $504 billion, or 2.8 percent of 
GDP that year (Council of Economic Advisors, 2017). A majority of these costs are attributed to 
nonfatal consequences such as healthcare spending, criminal justice costs, fatality costs, and lost 
productivity due to incarceration and addiction (Florence et al., 2016). The outcomes of 
increased opioid consumption include sharp increases in emergency room visits for overdose, 
neonatal abstinence syndrome, and increased mortality (SAMHSA, 2013). With an increase in 
morbidity and mortality rates due to opioids, it is necessary to utilize a multi-faceted public 
health approach that employs addiction prevention strategies.  
IMPACT ON HEROIN USE 
The opioid pain relievers (OPR) overdose death rate nearly quadrupled from 1999-2011 (Chen et 
al., 2014), as shown in Figure 6, and is now cited by the Centers for Disease Control and 
Prevention (CDC) as the “worst drug overdose epidemic in [US] history” (Paulozzi, 2010). It is 
important to recognize the relation between OPRs and heroin use. Statistics from the National 
Survey on Drug Use and Health (NSDUH) indicate 4 out of 5 heroin users began their addiction 
with OPRs and switched drugs because heroin was cheaper and easier to obtain (Muhuri et al., 
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2013). In 2014, national surveillance data showed that 914,000 individuals reported using heroin, 
which was a 145% increase from seven years prior (Center for Behavioral Health Statistics and 
Quality, 2014). When looking at the drug overdose crisis holistically, it is necessary to 
understand the relationship between heroin and opioids to avoid the error of shifting the problem 
from one drug to another unintentionally. 
 
Figure 6: Three Wave Rise of Opioid Use 
This graph overlays the increases of Heroin, Prescription Opioids, and Other Synthetic Opioids 
outlined in three distinct waves. The first wave began with the increased prescriptions for opioids 
which increased until 2010. This was when the prescriptions decreased yet patients remained 
addicted, many of them switched to heroin which is depicted by the rapid increase in overdose 
deaths.  
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HISTORY OF OPIOID ADDICTION IN THE UNITED STATES 
In the 1840s, there was an increase in the estimated national supply of opium and morphine 
imports, which throughout the next 50 years lead to a 538% increase in opioid consumption 
(Courtwright, 2001). There were many uses for the drug, including the common use of opium by 
soldiers to treat painful injuries. Physicians at this time often prescribed opiates to their patients 
as there were few alternatives and the etiology of many chronic and acute diseases were poorly 
understood. As many advancements in health occurred, the administration of morphine as a 
primary solution decreased through the means of educated, better-trained health practitioners 
(Blair, 1919). The rest of the 20th century saw the use of short-lasting, nonmedical opioid 
increase disproportionately in inner-city, minority populations (DuPont & Greene, 1973).  
 In 1996, the rate of opioid use began accelerating rapidly due in part to the introduction 
of OxyContin in 1995 by Purdue Pharma. This drug is an extended-release formula for morphine 
advertised under the claim that the risk of addiction was minimal to none. Indeed, OxyContin 
was advertised as appropriate for the treatment of chronic pain. In the seven years that followed 
the introduction of OxyContin, Purdue Pharma funded over 20,000 educational programs that 
encouraged the long-term use of OPRs for non-cancer related chronic pain (US GAO). Purdue 
Pharma financially supported groups such as The Joint Commission, the Federation of State 
Medical Boards, the American Academy of Pain Medicine, and the American Pain Society – all 
of whom advocated for the use of OPRs to treat pain (Fauber, 2012). In 2007, the executives of 
Purdue Pharma pleaded guilty in federal court to criminal charges about misleading health 
professionals and patients about OxyContin, and they agreed to pay $600 million in fines, one of 
the largest amounts paid by any drug company. The executives agreed to pay a total of $34.5 
million in fines for misbranding, which is a criminal violation (Meier, 2007).  
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 While there have been no long-term quality clinical trials on the efficacy of OPRs for 
non-cancer chronic pain, there have been surveys of patients indicating that even with opiates 
they still experience significant chronic pain (Eriksen et al., 2006). The Joint Commission’s 
federally mandated patient satisfaction surveys ask patients to rate how their experience in the 
hospital was related to pain. This experience relates to the increase in hospital use of OPRs as 
physicians administer more opiates to have patients provide higher ratings (Herzig et al., 2014).  
 Overall, the United States has had a complicated relationship with opioid use. In recent 
history, the rise in opioid overdose death has had three distinct waves, initially in the 1990s with 
the over-prescription of opioids. The second wave was in 2010 when there was a rapid increase 
in heroin deaths. The third wave since 2013 includes a rapid increase in overdose deaths due to 
synthetic opioids such as fentanyl (Centers for Disease Control and Prevention, 2017).  
WHO IS USING? 
From 2002 to 2012, the use of nonmedical opioids has gradually declined; however, overdose 
deaths, addiction treatment admissions, and other adverse public health outcomes related to 
OPRs have increased (SAMHSA (Substance Abuse Ment. Health Serv. Adm.), 2003).  
 The demographic that abuses non-medically prescribed opioids the most is the young 
adult population, age 18-25. However, the group with the greatest use of prescription opioids is 
among adults over the age of 26 (CDC, 2016). From 2013-2014 the rate of opioid overdose 
deaths for men was three times higher than those of women for populations age 18-34 within the 
state of Massachusetts (Massachusetts Department of Public Health, 2016). 
One study looking at unintentional opioid overdoses in Utah showed that 92% of those 
who had died from overdose were receiving legitimate opioid prescriptions for their chronic 
pain. Middle-aged white women aged 55-64 and the elderly visit their physicians with 
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complaints of pain the most frequently, with rates higher than any other demographic (Blackwell 
et al., 2014). White women aged 55-64 have experienced the largest increase in accidental opioid 
overdose deaths over the past decade (CDC, 2013). Death from overdose can occur in non-opioid 
addicted users, yet it is much more common in individuals who are addicted to opioids.  
 
Figure 7: National Overdose Deaths 2002-Provisional 2017 Involving Opioids 
This bar graph depicts the total number of overdose deaths in the United States that were 
involving opioid drugs with provisional data from 2017. A line overlay depicting male versus 
female deaths further divides this graph. There has been a 4.1-fold increase in the total number of 
deaths involving opioids in the time depicted. 
 
NATIONAL RESPONSE 
In October of 2017, the acting Health and Human Services (HHS) Secretary declared the opioid 
crisis a nationwide public health emergency. In April of the same year, the HHS presented a new 
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five-point Opioid Strategy. The priorities include: (1) improving access to prevention, treatment, 
and recovery support services; (2) targeting the availability and distribution of overdose-
reversing drugs; (3) strengthening public health data and collection; (4) supporting cutting-edge 
research on addiction and pain; and (5) advancing the practice of pain management (U.S. 
Department of Health and Human Services, 2018).  
 To improve access to treatment and recovery support services, the HHS submitted letters 
to the governors in every U.S. state offering $485 million in grant money in return for evidence-
based treatment and prevention activities. These grants from the Substance Abuse and Mental 
Health Services Administration complemented grants from the Comprehensive Addiction and 
Recovery Act (CARA). By providing the funds for a wide range of programs – training for 
health professionals, prevention programs, technological support, and monitoring programs – 
there is a focus on recognizing that individual states will tackle their state-wide crises at a level 
that is specific for their communities (Secretary for Health and Human Services, 2018).  Many 
states have given importance to opioid overdose reversal drugs such as naloxone. These drugs 
can reverse the effect of overdoses, and there is a focus on making them as affordable as possible 
while increasing access to them (Secretary for Health and Human Services, 2018).  
 The third priority in the Opioid Strategy is that of public health surveillance and research. 
A goal of the HHS is to increase cooperation between public health authorities and law 
enforcement. To accomplish this, the HHS is working with Customs and Border Protection, so 
that when shipments of opioids are intercepted, the local public health authorities are alerted in 
order to help them best prepare for an upcoming wave of overdoses (Secretary for Health and 
Human Services, 2018).  
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 Pain management is an incredibly important component in the discussion of finding 
lasting solutions for the opioid crisis. It is necessary to avoid creating dependence in the first 
place, including rethinking and revisiting the revolution that has occurred in pain management 
over the past several years. The Office of Assistant Secretary and the National Institute of Health 
(NIH) are working through the Interagency Task Force on Pain Management to implement a 
National Pain Strategy (Secretary for Health and Human Services, 2018). 
OVERDOSE TREATMENTS 
Morphine is an agonist at the mu-opioid receptor and by functioning as an antagonist at the mu-
opioid receptor; drugs such as naloxone can reverse overdoses. Naloxone has saved tens of 
thousands of lives, but administration must occur shortly after an overdose (Volkow & Francis, 
2017). There is a necessity for newer improved reversal drugs. The National Institute on Drug 
Abuse (NIDA) developed a Narcan Nasal Spray, which functions as an intranasal naloxone 
formula. This spray was an advancement in the field of treatments, as it would result in blood 
naloxone levels that were equivalent to if the naloxone had been administered parenterally. This 
drug is also available in an injection form. Some longer-term alternatives that will potentially be 
able to intervene against opioid-induced respiratory depression include 5-hydroxytryptamine 
type 1A (5-HT1A) agonists, ampakines, and phrenic-nerve-stimulation devices. These treatments 
would be most effective for those individuals that are at high risk for overdose (Volkow & 
Francis 2017). 
OPIOID USE DISORDER TREATMENTS 
There is no immediate solution for opioid addiction treatment. To maintain long-term recovery, 
sustained treatment over a prolonged period is necessary. However, three medications that are 
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approved for opioid use disorder: methadone via methadone maintenance treatments, 
buprenorphine, and extended-release naltrexone (Volkow et al., 2014). 
 Methadone Maintenance Treatment (MMT) involves having the opioid-dependent 
individual orally consume a daily dose of methadone under medical supervision. This treatment 
method aids in decreasing criminal activity often associated with obtaining illegal drugs (Volkow 
& Francis, 2017). There has been a development with buprenorphine treatment, which functions 
as a partial opioid agonist, which will produce lower levels of the side effects when compared to 
other opioids such as oxycodone and heroin. NIDA collaborated with pharmaceutical industries 
to develop an implant, Probuphine, which would deliver doses on a weekly or monthly period to 
the individual. This is an initial step towards long-term treatment methods and would work well 
for patients that have had nonfatal opioid overdoses (Volkow & Francis, 2017). Extended-release 
naltrexone is a monthly injectable formula of the mu-opioid receptor antagonist that is also used 
to prevent opioid dependence. There has been much promise shown for vaccines against 
prescription opioids, synthetic opioids, and heroin. These vaccines would function by inducing 
antibodies to prevent opioids from entering the brain (Bremer et al., 2016).  
CONCLUSION 
The opioid epidemic was not created in a vacuum. Surgeon and author Atul Gawande 
stated in an interview that it was doctors who have started the epidemic and it began as an effort 
to better treat pain, something that had previously been undertreated (Kliff, 2017). Moving 
forward it is important for the American Medical Association to ensure that physicians who are 
practicing in the United States are actively monitoring their patients and have safe methods to 
report any suspicious patterns. It is also necessary to create and enforce policies for healthcare 
providers that reflect the guidelines that are put in place from organizations such as the Centers 
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for Disease Control and Prevention. Pharmaceutical companies have also fueled the epidemic by 
using aggressive techniques to boost prescriptions. The American Pharmacists Association 
should focus on research that provides safer alternatives to opioid use for pain and couple these 
less aggressive pain treatments with ensuring that for those that are currently addicted, there are 
alternative medications at an affordable rate. A look at socioeconomic factors is also important, 
as a lack of health insurance, poverty, and unemployment are associated with a higher prevalence 
of prescription opioid disorder (Godlee, 2017). No biological treatment will address the lack of 
economic opportunity, and this will require action at an institutional level. Many insurance 
policies do not cover addiction treatments, and many individuals facing this crisis lack insurance. 
Nationally, a look towards expanding Medicaid will aid in increasing access to health insurance 
and should cover not just treatment but also preventive care. To create a more comprehensive 
opioid strategy, it will be necessary to build coalitions and partnerships with all the stakeholders 
involved through a collective impact model to guide decision making and collaborative 
approaches.  
 From the public health perspective, one of the solutions for many of the issues involved 
with this epidemic is that of improving accessibility and surveillance of data at local levels. By 
having data-driven frameworks present at local levels, interventions will be more adaptive to 
their respective regions and can be monitored for successes. It will also promote collaboration 
between the different areas that are involved in finding solutions- research, industry, and 
government.  
Throughout the history of medicine, one of the strongest allies in resolving public health 
crises has been the field of science. With regards to the opioid epidemic, science needs to be at 
the forefront of the discussion regarding treatment. It is necessary to increase inter-agency 
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collaboration and recognize the true extent that this crisis spans. This current epidemic is 
multifaceted and involves many different agencies: pharmaceutical companies, medical 
professionals, educators, border control agents, governmental agencies such as the FDA & 
NIDA, law enforcement, and scientists. Better coordination of community involvement and 
allocating funds towards appropriate resources are some initial steps that should be taken to 
combat this epidemic. Finding alternate solutions to pain management that do not involve the 
administration of addictive opioids is imperative. Looking forward, a public health approach that 
focuses on evidence-based scientific tools will help to end this current crisis and prevent it from 
reemerging in the future.  
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